Gary Rolband, MD
Endocrinology, Diabetes & Metabolism · Charlotte, NCNPI 1730106386
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,007 of the $5,906 with a category attached, or 84.8%. It is spread thinly across 47 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.
Across 245 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1K
- Amgen$485
- Lilly USA, LLC$424
- Novo Nordisk$360
- Insulet Corporation$323
- Radius Health, Inc.$323
- plus $3K from 41 others
Across 7 payments — averaging $1841.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$11K
- Shire North American Group Inc$2K
What the payments were for
- Travel & lodging$87515%
- Food & beverage$5,00785%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,906 in reported general payments places this provider in the 70th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 267 | $397,138 |
| TrulicityDulaglutide | 148 | $209,958 |
| MounjaroTirzepatide | 123 | $155,752 |
| FarxigaDapagliflozin Propanediol | 110 | $119,733 |
| JardianceEmpagliflozin | 82 | $94,384 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $49,704 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $46,704 |
| JanuviaSitagliptin Phosphate | 27 | $30,894 |
| SynthroidLevothyroxine Sodium | 281 | $26,939 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $24,143 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $23,946 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $20,129 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $15,306 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $15,267 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $15,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $360 | $406,041308 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $424 | $379,995318 claims |
| AstraZenecaFarxiga | $63 | $119,733110 claims |
| Boehringer IngelheimJardiance | $161 | $94,38482 claims |
| AbbVieSynthroid, Armour Thyroid | $87 | $32,558340 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $229 | $24,14315 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $163 | $5,517634 claims |
| PfizerLevoxyl | $27 | $1,15221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Charlotte
- Charles UpchurchCharlotte$343K
- Adam SpitzCharlotte$33K
- Raymond StadiemCharlotte$32K
- Nisha NathanCharlotte$31K
- David BrantleyCharlotte$27K
- Kanakasabai NarasimhanCharlotte$25K
- Elizabeth HarrisCharlotte$10K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.